Trials / Completed
CompletedNCT01437111
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
A Phase III (Phase IV Program) Open-Label, Multicenter Clinical Trial in Thailand to Study the Effect of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) for 6 Months on 25-Hydroxyvitamin D Levels in the Treatment of Osteoporosis in Postmenopausal Women and Men
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the effect of 26 weeks of once-weekly treatment with MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) on serum levels of 25-hydroxyvitamin D \[25(OH)D\].
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet | One combination tablet orally once a week |
Timeline
- Start date
- 2011-10-26
- Primary completion
- 2012-12-05
- Completion
- 2012-12-05
- First posted
- 2011-09-20
- Last updated
- 2024-04-22
- Results posted
- 2014-01-22
Source: ClinicalTrials.gov record NCT01437111. Inclusion in this directory is not an endorsement.